Timothy DeVere Cook - 20 Jul 2022 Form 4 Insider Report for Athenex, Inc.

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Jul 2022
Net transactions value
$0
Form type
4
Filing time
21 Jul 2022, 17:20:03 UTC
Previous filing
18 Jul 2022
Next filing
01 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNXQ Common Stock 8,133 20 Jul 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Stock Option (Right to Buy) Award $0 +75,000 $0.000000 75,000 20 Jul 2022 Common Stock 75,000 $0.6655 Direct F6
holding ATNXQ Stock Option (Right to Buy) 70,000 20 Jul 2022 Common Stock 70,000 $17.29 Direct F1
holding ATNXQ Stock Option (Right to Buy) 30,000 20 Jul 2022 Common Stock 30,000 $10.26 Direct F2
holding ATNXQ Stock Option (Right to Buy) 9,000 20 Jul 2022 Common Stock 9,000 $3.56 Direct F3
holding ATNXQ Restricted Stock Units 9,000 20 Jul 2022 Common Stock 9,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests in four equal annual installments beginning on August 16, 2019.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F6 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs